Views and missives from the frontier
Our Latest Press ReleasesRead All Press Releases
CAMP4 is pioneering drug development targeting regulatory RNAs, the next frontier in the non-coding genome. Our ongoing series on the “dark genome” explains this new area of biology, our approach, and the vast potential of our platform to create medicines that solve to address thousands of genetic diseases.
CAMP4’s scientific founders share insights around regRNAs, the master controls of gene expression, and how this discovery is enabling a drug target class that could be game-changing for a wide range of diseases.
Featuring:Rick Young, Ph.D., Leonard Zon, M.D.
CAMP4 takes a novel approach to addressing genetic diseases with the potential to have a therapeutically meaningful impact on patients’ lives.
Featuring:Ann Barbier, M.D., Ph.D., Josh Mandel-Brehmm
By targeting the regulatory components of transcription that play a central role in gene expression, CAMP4 has opened a new area of biology for drug discovery.
Featuring:Benjamin Neale, Ph.D., David Bumcrot, Ph.D., Richard Young, Ph.D., Ann Barbier, M.D., Ph.D.
Combining the power of AI with proprietary, high-quality data sets, CAMP4 is illuminating the dark side of the genome.
Featuring:David Bumcrot, Ph.D., Benjamin Neale, Ph.D.
Controlling gene expression by targeting regRNAs offers enormous potential to help patients across a wide range of genetic diseases.
Featuring:Richard Young, Ph.D., Alfica Sehgal, Ph.D., Josh Mandel-Brehm, Benjamin Neale, Ph.D.